

1. NAME OF THE VETERINARY MEDICINAL PRODUCTS

Qualimec 10 mg/ml solution for injection for cattle, sheep and pigs

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

Active substances:

Ivermectin: 10 mg

Excipients:

Qualitative composition of excipients and other constituents	Quantitative composition if that information is essential for proper administration of the veterinary medicinal product
Benzyl alcohol	10 mg
Ethanol 96%	
Propylene glycol	
Water for injections	

A clear, colourless solution.

3. CLINICAL INFORMATION

3.1 Target species

Cattle, sheep and pigs.

3.2 Indications for use for each target species

Cattle:

For the treatment of gastrointestinal nematodes, lungworms, eyeworms, warble flies, mites and lice (as shown below) of beef and non-lactating dairy cattle:

Gastrointestinal worms (adults and 4th stage larvae):

Ostertagia ostertagi

Ostertagia lyrata

Haemonchus placei

Trichostrongylus colubriformis

Cooperia oncophora (adults)

Cooperia punctata (adults)

Cooperia pectinata (adults)

Bunostomum phlebotomum

Oesophagostomum radiatum

Lungworms (adult and 4th stage larvae):

Dictyocaulus viviparus

Eyeworms (adult):

Thelazia spp.

Warble flies (parasitic stages):

Hypoderma bovis

H. lineatum

Mites:

Psoroptes ovis

Sarcoptes scabiei var. *bovis*

Sucking lice:

Linognathus vituli

Haematopinus euryesternus

Solenopotes capillatus

May also be used as an aid in the control of the mange mite *Chorioptes bovis* but complete elimination may not occur.

Treatment with the veterinary medicinal product at the recommended dose rate prevents re-infection with *Haemonchus placei*, *Cooperia oncophora*, *Cooperia pectinata* and *Trichostrongylus axei* for 7 days after treatment, *Ostertagia ostertagi* and *Oesophagostomum radiatum* for 14 days after treatment and *Dictyocaulus viviparus* for 21 days after treatment.

Sheep:

For the treatment of psoroptic mange (sheep scab), gastrointestinal nematodes, lungworms and nasal bots of sheep:

Gastrointestinal roundworms (adults):

Ostertagia circumcincta

Haemonchus contortus

Trichostrongylus axei

T. colubriformis and *T. vitrinus*

Cooperia curticei

Nematodirus filicollis

Variable activity may be observed against *Cooperia curticei* and *Nematodirus filicollis*.

Lungworms:

Dictyocaulus filaria (adults)

Mange mites:

Psoroptes ovis

Nasal bot:

Oestrus ovis (all larval stages)

Pigs:

For the treatment of gastro-intestinal nematodes, lungworms, lice and mange mites of pigs.

Gastro-intestinal worms (adult and 4th stage larvae):

Ascaris suum

Hyoststrongylus rubidus

Oesophagostomum spp.

Strongyloides ransomi (adults).

Lungworms:

Metastrongylus spp. (adults)

Lice:

Haematopinus suis

Mange Mites:

Sarcoptes scabiei var. *suis*

3.3 Contraindications

Do not use in cases of hypersensitivity to the active substances or to any of the excipients.

Do not administer by the intravenous or intramuscular route.

3.4 Special warnings

Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy:

- Too frequent and repeated use of anthelmintics from the same class, over an extended period of time.
- Underdosing, which may be due to underestimation of bodyweight, misadministration of the product, or lack of calibration of the dosing device (if any).

Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used.

Treatment of psoroptic mange (sheep scab) with one injection is not recommended because, although clinical improvement may be seen, elimination of all mites may not occur.

Sheep scab (*Psoroptes ovis*) is an extremely contagious external parasite of sheep. Following treatment of infected sheep great care must be taken to avoid re-infestation as mites may be viable for up to 15 days off the sheep. It is important to ensure all sheep which have been in contact with infected sheep are treated. Contact between treated infected and non-treated, non-infected flocks must be avoided until at least 7 days after the last treatment.

Resistance to ivermectin has been reported in *Ostertagia circumcincta* in lambs and in *Ostertagia ostertagi* in cattle. Therefore, the use of this veterinary medicinal product should be based on local (regional, farm) epidemiological information about susceptibility of these *helminth species* and recommendations on how to limit further selection for resistance to anthelmintics.

3.5 Special precautions for use

Special precautions for safe use in the target species:

Do not combine treatment with vaccination against lungworms. If vaccinated animals are to be treated, treatment should not be carried out within a period of 28 days before or after vaccination.

The shedding of nematode eggs can continue for some time after treatment.

In Cattle: To avoid secondary reactions due to the death of *Hypoderma* larvae in the oesophagus or in the spine, it is recommended to administer the veterinary medicinal product at the end of warble fly activity and before the larvae reach their resting sites.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Do not smoke, eat or drink while handling the veterinary medicinal product.

Wash hands after use.

Take care to avoid self-injection: the veterinary medicinal product may cause local irritation and/or pain at the site of injection.

Special precautions for the protection of the environment:

Not applicable.

Other precautions:

Avermectins may not be well tolerated in non-target species. Cases of intolerance with fatal results are reported in dogs – especially Collies, Old English Sheepdogs and related breeds and crosses, and also in turtles/tortoises.

3.6 Adverse events

Cattle, sheep and pigs:

Undetermined frequency (cannot be estimated from the available data):	Discomfort ^{1,2} , Injection site swelling ³ , Injection site thickening ³
---	--

¹ Transient, immediately following after subcutaneous administration.

² In cattle jumping and rolling may occur, but behaviour returns to normal after 15 minutes.

³ Transient, typically disappears within 1 to 4 weeks.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:

Can be used during pregnancy in cows, ewes and sows.

Do not use in lactating cows producing milk for human consumption. Do not use in non-lactating dairy cows, including pregnant dairy heifers, within 60 days of calving.

Do not use in lactating ewes producing milk for human consumption. Do not use in sheep which are intended to produce milk for human consumption within 60 days of lambing.

Fertility:

The fertility of males is not affected by administration of the veterinary medicinal product.

3.8 Interaction with other medicinal products and other forms of interaction

Do not combine ivermectin treatment with vaccination against lungworms. If vaccinated animals are to be treated, treatment should not be carried out within a period of 28 days before or after vaccination (see section 3.5).

3.9 Administration routes and dosage

Subcutaneous use.

For single administration only (except for the treatment of *Psoroptes ovis* infections in sheep).

To ensure a correct dosage, bodyweight should be determined as accurately as possible. Accuracy of the dosing device should be checked.

If animals are to be treated collectively rather than individually, they should be grouped according to their bodyweight and dosed accordingly, in order to avoid under- or over-dosing.

When using the 200, 250 or 500 ml pack sizes, use only automatic syringe equipment. For the 50 ml pack size, use of a multiple dose syringe is recommended. To refill the syringe, use of a draw-off needle is recommended to avoid excessive breaching of the stopper.

Swab septum before removing each dose.

Cattle

Dosage:

1.0 ml per 50 kg bodyweight (based on a recommended dosage level of 200 micrograms ivermectin per kg bodyweight).

Administration:

Inject subcutaneously in front of, or behind, the shoulder using aseptic technique. A sterile 1.4 x 15 mm (17G x ½ inch) needle is recommended.

Sheep

Dosage:

0.5 ml per 25 kg of bodyweight (based on a recommended level of 200 micrograms ivermectin per kg bodyweight).

Administration:

For the treatment of gastrointestinal roundworms, lungworms and nasal bots inject once subcutaneously in the neck, using aseptic precautions; a sterile 1.4 x 15 mm (17G x ½ inch) needle is recommended.

For the treatment of *Psoroptes ovis* (sheep scab), two injections with a seven-day interval are required to treat clinical signs of scab and to eliminate living mites.

For young lambs weighing less than 20.0 kg give 0.1 ml per 5 kg. In these lambs the use of a syringe which can deliver as little as 0.1 ml is recommended.

Pigs

Dosage:

1.5 ml per 50 kg bodyweight (based on a recommended dosage level of 300 micrograms ivermectin per kg bodyweight).

Administration:

The recommended route of administration is by subcutaneous injection into the neck using aseptic technique and a sterile 1.4 x 15 mm (17G x ½ inch) needle.

For piglets weighing less than 16 kg give 0.1 ml per 3 kg. In these piglets the use of a syringe which can deliver as little as 0.1 ml is recommended.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

Clinical symptoms of ivermectin toxicity include ataxia and depression. No antidote has been identified. In case of overdose, symptomatic treatment should be given. No signs of toxicity were observed in animals treated at up to 3 times the recommended dose rate.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance.

Not applicable.

3.12 Withdrawal periods

Cattle:

Meat and offal: 49 days.

Do not use in lactating cows producing milk for human consumption.

Do not use in non-lactating dairy cows, including pregnant dairy heifers, within 60 days of calving.

Sheep:

Meat and offal: 42 days.

Do not use in lactating ewes producing milk for human consumption.

Do not use in sheep which are intended to produce milk for human consumption within 60 days of lambing.

Pigs:

Meat and offal: 28 days.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code : QP54AA01.

4.2 Pharmacodynamics

Ivermectin is a macrocyclic lactone derivative and acts by inhibiting nerve impulses. It binds selectively and with high affinity to glutamate-gated chloride ion channels which occur in invertebrate nerve and muscle cells. This leads to an increase in the permeability of the cell membrane to chloride ions with hyperpolarization of the nerve or muscle cell, resulting in paralysis and death of the relevant parasites. Compounds of this class may also interact with other ligand-gated chloride channels, such as those gated by the neurotransmitter gammaaminobutyric acid (GABA). The margin of safety for compounds of this class is attributable to the fact that mammals do not have glutamate-gated chloride channels. The macrocyclic lactones have a low affinity for other mammalian ligand-gated chloride channels and they do not readily cross the blood-brain barrier.

4.3 Pharmacokinetics

In each of the target species the pharmacokinetic profile following subcutaneous administration was characterised as follows (pharmacokinetic parameters presented as mean values):

Following administration to cattle, C_{max} was 51 ng/ml, with a T_{max} of 43 h, $T_{1/2}$ of 129 h and an AUC of 7398 ng.h/ml.

Following two subsequent administrations seven days apart to sheep, C_{max} was 14 ng/ml, with a T_{max} of 202 h, $T_{1/2}$ of 380 h and an AUC of 4686 ng.h/ml.

Following administration to pigs, C_{max} was 6.35 ng/ml, with a T_{max} of 106 h, $T_{1/2}$ of 219 h and an AUC of 1260 ng.h/ml.

Only about 2% of the drug is excreted in urine, faecal excretion being the major route of elimination. Tissue residues of radioactivity following subcutaneous administration of tritium-labelled ivermectin are highest in liver and fat; lowest levels are found in brain.

In cattle, the residual antiparasitic effect of ivermectin is due to its persistence which in turn is due in part to its long intrinsic half-life and its relatively high protein binding (90%).

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
Shelf life after first opening the immediate packaging: 28 days.

5.3 Special precautions for storage

Store below 25 °C.
Protect from direct sunlight.
Keep the container in the outer carton in order to protect from light.

5.4 Nature and composition of immediate packaging

Carton box with one HDPE multidose container with bromobutyl rubber stopper and aluminium cap.
Pack sizes: 50 ml, 200 ml and 500 ml.

Carton box with one clear PET multidose container with bromobutyl rubber stopper and aluminium cap.
Pack sizes: 50 ml, 250 ml and 500 ml.

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

The veterinary medicinal product should not enter water courses as ivermectin may be EXTREMELY DANGEROUS TO FISH AND AQUATIC ORGANISMS.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

ECO Animal Health Europe Limited

7. MARKETING AUTHORISATION NUMBER(S)

VPA22693/002/001

8. DATE OF FIRST AUTHORISATION

01/10/1999

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

14/08/2026

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.
Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).